# Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT01235442** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 592 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 1=Etanercept
- **DRUG:** 2=Clobetasol propionate foam

## Key facts

- **NCT ID:** NCT01235442
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-10
- **Final completion:** 2011-12
- **Target enrollment:** 592 (ACTUAL)
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235442, "Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01235442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*